All Posts Tagged With: "ACL"
(WMGI) Wright Medical Group Gets a New CEO
International orthopedic devices company Wright Medical Group (WMGI) recently reported that its Board of Directors chose Mr. Robert J. Palmisano as President and CEO, starting from September 17, 2011. Mr. David D. Stevens, who was interim President and CEO, will remain Chairman...
21Sep2011 | vitalstocks | 0 comments | Continued(ABV) Company News for December 15, 2010 – Corporate Summary
• Joy Global (NASDAQ:JOYG) reported fiscal fourth quarter earnings of $1.39, ahead of the Zacks Consensus Estimate of $1.16, on revenues of $1.05 billion that topped the Zacks Consensus Estimate of $925.0 million. The firm provided upside 2011 guidance of $5.00-$5.30, above...
15Dec2010 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
15Nov2010 | vitalstocks | 0 comments | Continued(ACL) A Food Fight Over Nutraceuticals
by Tony D’Altorio, Investment U Research Monday, October 18, 2010 At first glance, the food and drug industries have very little in common. One is a relatively slow and safe business, the other a high-risk, high-reward venture. Yet these days, they seem to be moving in a...
18Oct2010 | InvestmentU | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
26Jul2010 | vitalstocks | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
20Jul2010 | vitalstocks | 0 comments | Continued(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Apr2010 | vitalstocks | 0 comments | Continued(ACL) Alcon Completes Product Deals
Alcon, Inc. (ACL) recently announced that it has acquired rights to two topical eye care products, Durezol and Zyclorin, from Sirion Therapeutics, Inc. Alcon also said that it is evaluating options to acquire another product, Zirgan, which is approved for the treatment of acute...
31Mar2010 | vitalstocks | 0 comments | Continued(ACL) Alcon – Solid Growth Across All Segments – Novartis Wants to Acquire Alcon
Alcon (ACL) is delivering solid growth across all business segments and pays a dividend yield of 2.3%. Company Description Alcon is one of the world’s leading suppliers of eye care products. The company has three operating segments: Pharmaceutical, which develops glaucoma...
3Mar2010 | vitalstocks | 0 comments | Continued(ACL) Alcon Beats Earnings Expectations on Strong Revenues
Alcon Inc. (ACL) reported fourth quarter earnings of $1.61 per share, easily beating the Zacks Consensus Estimate of $1.50 and 14.2% above the year-ago earnings of $1.41. Full year earnings came in at $6.81, 10 cents above the Zacks Consensus Estimate and 13.5% above the year...
15Feb2010 | vitalstocks | 0 comments | Continued(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Jan2010 | vitalstocks | 0 comments | Continued(ACL) Novartis’ Purchase Offer Inadequate for Alcon
Eye care company Alcon, Inc. (ACL) announced that its Independent Director Committee recently responded to Novartis AG’s (NVS) proposal to acquire its minority publicly traded shares. The Committee referred to the proposal as “grossly inadequate” and “fundamentally...
21Jan2010 | vitalstocks | 0 comments | Continued(ACL) Alcon Strengthens Product Pipeline
Alcon, Inc. (ACL) continues to work on expanding its product portfolio. The company recently entered into an agreement with Sirion Therapeutics, Inc. for the purchase of rights to two topical eye care products, Durezol and Zirgan. Both products have been approved by the US Food...
20Jan2010 | vitalstocks | 0 comments | Continued(NVS) Novartis Collaborates with GenVec on Hearing Loss Treatments
Recently, Novartis (NVS) entered into a collaboration with GenVec (GNVC) for the development of treatments for hearing loss and balance disorders. Earlier, preclinical results have found strong potential in GenVec’s adenovector technology for the restoration of hearing...
20Jan2010 | vitalstocks | 0 comments | Continued(ACL) What Nestle Wants Nestle Gets – And Right Now, Nestle Wants a Bigger Slice of the Pie
by Tony Daltorio, Investment U Research Monday, January 18, 2010 It would take far too long to list the leading brands Nestle ADR (OTC: NSRGY) owns, considering that it’s the world’s biggest food corporation with operations in almost every country. Suffice it to say however,...
18Jan2010 | InvestmentU | 0 comments | Continued(PFE) Novartis Sees Profits In Alcon – Why You Should Too
Tony Daltorio, Investment U Research Tuesday, January 12, 2010 Back in October, I wrote about how pharmaceutical companies captured the financial world’s attention with a myriad of lucrative mergers and acquisitions last year. Some of the more memorable deals included...
12Jan2010 | InvestmentU | 0 comments | Continued(KFT) Kraft Foods Offers More Cash for Cadbury
Kraft Foods (KFT) has agreed to sell its North American pizza business to Nestle for $3.7 billion in cash. The transaction is expected to close in 2010. The sale includes the DiGiorno, Tombstone and Jack’s brands in the U.S., the Delissio brand in Canada and the California...
5Jan2010 | vitalstocks | 0 comments | Continued(NVS) Novartis Announces Intent to Gain Full Ownership of Alcon
Novartis (NVS) has recently announced that it intends to gain full ownership of eye care company Alcon Inc. (ACL). Novartis will first complete its April 2008 agreement with Nestlé S.A. whereby it will acquire a majority stake (77%) in Alcon. Of this, Novartis acquired a 25%...
5Jan2010 | vitalstocks | 0 comments | Continued(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between...
9Nov2009 | Shawn | 0 comments | Continued(ACL) Alcon Continues to Grow Pipeline
Alcon, Inc. (ACL) recently entered into an in-licensing agreement with Potentia Pharmaceuticals, a privately-held biotechnology company that focuses on the development of medicines for the treatment of age-related macular degeneration (AMD). Alcon gained the right to develop...
26Oct2009 | vitalstocks | 0 comments | Continued(ACL) Alcon Aquires Swiss Company and Expands Pipeline
Earlier this week, Alcon Inc. (ACL) signed a definitive agreement for the acquisition of Swiss biotech company ESBATech AG. Alcon will pay $150 million in cash at closing. Besides this, Alcon may pay up to $439 million on the achievement of future research and development milestones. With...
18Sep2009 | vitalstocks | 0 comments | Continued(ISTA) ISTA Pharmaceuticals Eye Drug Gets FDA Approval
Yesterday, ISTA Pharmaceuticals Inc. (ISTA) announced that the U.S. Food and Drug Administration (FDA) approved its drug candidate, Bepreve, for the treatment of ocular itching associated with allergic conjunctivitis in patients two years and above. The drug is approved as a...
9Sep2009 | vitalstocks | 0 comments | Continued(ABT) Abbott Expands Ophthalmic Portfolio
Abbott (ABT) yesterday entered into a definitive agreement whereby it will acquire Visiogen, Inc., a privately-held company, for $400 million in cash. Visiogen is focused on the development of innovative products for cataract and refractive patients. The deal will provide Abbott...
3Sep2009 | vitalstocks | 0 comments | Continued(ISTA) ISTA Pharmaceuticals’s Eye Drug Shows Success
ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye. ISTA...
27Aug2009 | vitalstocks | 0 comments | Continued(AGN) Allergan Receives FDA Warning
On Aug. 21, Allergan, Inc. (AGN) received a warning letter from the U.S. Food and Drug Administration’s (FDA) Division of Drug Marketing, Advertising and Communications (DDMAC) regarding a misleading advertisement used by the company for its acne treatment Aczone Gel, 5%. Aczone...
25Aug2009 | vitalstocks | 0 comments | Continued